KRAS and pancreatic adenocarcinoma: He et al. showed that alterations in the transcription factor GLI1 lead to alterations in the methyltransferases DNMT1 and DNMT3a, which favour the methylation of genes, such as p16, which is altered in 95% of patients with pancreatic adenocarcinoma, or KRAS [123].